TABLE 2.
Predicted Cumulative Absorbed Doses to Normal Organs and Target Lesions Calculated Per Unit of Activity and for Four Planned Administrations of 7.4 GBq (29.6 GBq total) of 177Lu-DOTATATE (n = 20)
| Absorbed dose per unit activity (Gy/GBq) | Absorbed dose for four 7.4 GBq (29.6 GBq in total) (Gy) | |||
|---|---|---|---|---|
| Organ | Mean (SD) | Median (range) | Mean (SD) | Median (range) |
| Kidneys | 0.65 (0.30) | 0.68 (0.16–1.17) | 19.4 (8.7) | 19.3 (4.8–34.6) |
| Liver* | 0.30 (0.23) | 0.33 (0.05–2.06) | 8.9 (6.7) | 6.8 (1.6–23.7) |
| Red marrow from blood | 0.04 (0.03) | 0.03 (0.01–0.14) | 1.0 (0.8) | 0.7 (0.3–4.1) |
| Spleen | 0.85 (0.80) | 0.62 (0.18–3.61) | 25.1 (23.8) | 18.2 (5.4–106.9) |
| Urinary bladder wall | 0.44 (0.18) | 0.4 (0.2–0.8) | 12.8 (5.3) | 11.9 (4.5–22.6) |
| Total body | 0.05 (0.03) | 0.05 (0.01–0.1) | 1.6 (0.8) | 1.6 (0.4–3.1) |
| Tumor lesions† | 7.6 (10.6) | 4.5 (0.2–74.9) | 224 (313) | 134 (7–2,218) |
*
n = 18 (2 patients were nonevaluable because of high tumor burden).
†
65 lesions from 17 patients.